Adding abiraterone and prednisone to androgen-deprivation therapy significantly improved survival.
Mortality was highest in patients with ADAMTS13 antibody levels in the highest quartile and ADAMTS13 antigen levels in the lowest quartile.
Small Peruvian study suggests prior CBE may lead women with self-detected breast cancer to present earlier for care.
The hematologic response rate was 52% among patients who received the maximum tolerated dose.
Survival with drug-antibody conjugate trastuzumab emtansine was not superior to that with taxane therapy.
Consolidative autologous SCT did not improve survival for patients in first remission after induction chemoimmunotherapy.
Patients with luminal B tumors respond better to postoperative androgen-deprivation therapy than do those with non–luminal B tumors.
Complete response was achieved by 40% of patients.
Intratumor heterogeneity is associated with an increased risk for disease recurrence or death.
A phase II trial demonstrates activity in patients with chemotherapy-refractory disease.
Prof. Dr. med. Florian Otto
Tumor- und Brustzentrum ZeTuP, St. Gallen
E-Mail: E-Mail anzeigen
Immuntherapie ist in aller Munde. Checkpoint-Inhibitoren werden bei praktisch allen onkologischen Erkrankungen erprobt und erweisen sich häufig als wirksam – zumindest für eine gewisse Zeit. Aber wie entwickelt sich eine Resistenz? Dieser Frage sind Zaretsky und Kollegen im Kontext von vier Melanompatienten unter Pembrolizumab-Therapie nachgegangen und haben Defekte im Interferon-Signalweg sowie der Antigenpräsentation in den Tumorzellen gefunden.
Mortality was similar with active monitoring, prostatectomy, or radiotherapy during 10 years of follow-up.
Pregnant women with inherited thrombophilia have increased risk for VTE, independent of a family history of VTE.
The use of >12 serum tumor marker tests and/or 4 radiographic imaging tests per year provided no survival advantage.
Adding epirubicin to fluorouracil/platinum-based chemotherapy resulted in greater toxicity and no clear improvement in response.
Andexanet reduced anti–factor Xa activity and restored effective hemostasis in patients with major bleeding.
A 70-gene signature identified patients with high clinical risk and low molecular risk who achieved a 5-year survival rate of 94.7% without chemotherapy.
Declines in light chain levels were achieved in heavily pretreated patients.
The HER2-targeted combination regimen of trastuzumab and lapatinib may have activity in HER2-positive, chemotherapy-refractory disease.
Mutations preventing interferon-receptor signaling and antigen presentation are linked to acquired resistance.
Overall survival was significantly better with S-1 versus gemcitabine.